Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 4/20 | 0.43 |
| ▸ | GCGR | P47871 | 4/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20401786 | 0.84 | MAPK13 (0.46) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL417139 | 0.83 | NISCH (0.45) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL2304276 | 0.79 | POLB (0.39) | MAPTNPC1RAB9APOLBL3MBTL1 | |
| SCHEMBL415765 | 0.79 | MAPK1 (0.47) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL416642 | 0.79 | POLB (0.56) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL7119605 | 0.79 | RPS6KA3 (0.45) | MAPK14MAPTTNKSTNKS2NPC1 | |
| SCHEMBL416435 | 0.78 | POLB (0.60) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL15884146 | 0.77 | NPC1 (0.36) | MAPTNPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL16661157 | 0.77 | ALDH1A1 (0.58) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL420012 | 0.77 | MGAM (0.43) | MAPK13GCGRMAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4251625-A1 | TRICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143394-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008077649-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | MAPK13 1830/4885GCGR 1314/4885MAPK12 2463/4885 |
| US-20090324543-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PLPBP | MAPK13 3534/4885GCGR 4210/4885MAPK12 4091/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | MAPK13 1830/4885GCGR 1314/4885MAPK12 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.